세계의 프로클로르페라진 말레산 시장 : 적응증별, 투여형별, 유통 채널별, 최종 사용자별, 지역별

Prochlorperazine Maleate Market is estimated to be valued at USD 1.61 Bn in 2025 and is expected to reach USD 2.03 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.4% from 2025 to 2032.

Prochlorperazine maleate is utilized for treating severe nausea and vomiting as well as to help people with schizophrenia or anxiety have better moods, thinking, and conduct. It is a member of the phenothiazine class of drugs. The way this drug affects brain chemistry is how it functions. Dopamine, a neurotransmitter that aids in movement and pleasure, might then be produced in greater amounts by the body as a result. It can also mask more serious illnesses that produce nausea and vomiting, such as drug overdose or poisoning, brain tumors, brain injuries, or Reye's syndrome. A medicine from the phenothiazine class of antipsychotics is called prochlorperazine maleate.

Market Dynamics:

The increasing frequency of vomiting and nausea will continue to fuel growth of the global prochlorperazine maleate market over the forecast period. The number of people requiring antiemetic therapy is rising as a result of rising chronic disease prevalence and an aging population. Growing patient awareness will also continue to fuel growth of the global prochlorperazine maleate market over the forecast period. Patients are more active in seeking out the right therapy alternatives and talking about their issues with medical providers. The creation of combination therapies will create new opportunities for the global prochlorperazine maleate market over the forecast period. There is potential for market growth in the investigation of combination medicines containing prochlorperazine maleate.

Safety issues and negative side effects are expected to hamper growth of the global prochlorperazine maleate market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global prochlorperazine maleate market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global prochlorperazine maleate market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline plc, Pfizer Inc., Novartis AG, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global prochlorperazine maleate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prochlorperazine maleate market

Global Prochlorperazine Maleate Market Detailed Segmentation:

• By Indication:
  • Nausea and Vomiting Management
  • Vertigo
  • Mental Health Disorders (e.g., Schizophrenia)
• By Dosage Form:
  • Oral Tablets
  • Rectal Suppositories
  • Injectable Formulations
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End User:
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
• By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profile:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • Johnson & Johnson
  • AbbVie Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Pu rview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Prochlorperazine Maleate, By Indication
  • Market Prochlorperazine Maleate, By Dosage Form
  • Market Prochlorperazine Maleate, By Distribution Channel
  • Market Prochlorperazine Maleate, By End User
  • Market Prochlorperazine Maleate, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Prochlorperazine Maleate Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Prochlorperazine Maleate Market , By Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Nausea and Vomiting Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vertigo
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Motion Sickness
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Prochlorperazine Maleate Market , By Dosage Form, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Rectal Suppositories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Injectable Formulations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Prochlorperazine Maleate Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Prochlorperazine Maleate Market , By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2020-2032,(US$ Bn)
• North Africa
• South Africa
• Central Africa

9. Competitive Landscape

• Sandoz Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• ABneal Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Glenmark Pharmaceuticals Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Aurobindo Pharma Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Aspen Pharma Trading Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• FAGRON
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us